Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

3期 已完成 NCT05989126

摘要

Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye. A PFS offers a sterile, single dose of study drug within the syringe; this eliminates the need for the retina specialist to prepare the injection syringe from a separate vial. This Phase IIIb study is focused on patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD). The main aim of the study is to evaluate if the 8 mg aflibercept PFS allows for successful preparation and administration of 8 mg aflibercept by retina specialists. The study will also assess the safety of 8 mg aflibercept PFS use. Regeneron will use the information from the study to better understand if the PFS can be used safely and effectively by retina specialists to administer 8 mg aflibercept.

Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS

At Day 1 · injections

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

全部试验